IBDEI2D7 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40102,1,4,0)
 ;;=4^C83.58
 ;;^UTILITY(U,$J,358.3,40102,2)
 ;;=^5001589
 ;;^UTILITY(U,$J,358.3,40103,0)
 ;;=C83.78^^156^1952^15
 ;;^UTILITY(U,$J,358.3,40103,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40103,1,3,0)
 ;;=3^Burkitt lymphoma, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,40103,1,4,0)
 ;;=4^C83.78
 ;;^UTILITY(U,$J,358.3,40103,2)
 ;;=^5001599
 ;;^UTILITY(U,$J,358.3,40104,0)
 ;;=C83.18^^156^1952^35
 ;;^UTILITY(U,$J,358.3,40104,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40104,1,3,0)
 ;;=3^Mantle cell lymphoma, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,40104,1,4,0)
 ;;=4^C83.18
 ;;^UTILITY(U,$J,358.3,40104,2)
 ;;=^5001569
 ;;^UTILITY(U,$J,358.3,40105,0)
 ;;=C83.38^^156^1952^23
 ;;^UTILITY(U,$J,358.3,40105,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40105,1,3,0)
 ;;=3^Diffuse large B-cell lymphoma, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,40105,1,4,0)
 ;;=4^C83.38
 ;;^UTILITY(U,$J,358.3,40105,2)
 ;;=^5001579
 ;;^UTILITY(U,$J,358.3,40106,0)
 ;;=C84.68^^156^1952^12
 ;;^UTILITY(U,$J,358.3,40106,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40106,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-pos, nodes mult site
 ;;^UTILITY(U,$J,358.3,40106,1,4,0)
 ;;=4^C84.68
 ;;^UTILITY(U,$J,358.3,40106,2)
 ;;=^5001659
 ;;^UTILITY(U,$J,358.3,40107,0)
 ;;=C84.78^^156^1952^11
 ;;^UTILITY(U,$J,358.3,40107,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40107,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-neg, nodes mult site
 ;;^UTILITY(U,$J,358.3,40107,1,4,0)
 ;;=4^C84.78
 ;;^UTILITY(U,$J,358.3,40107,2)
 ;;=^5001669
 ;;^UTILITY(U,$J,358.3,40108,0)
 ;;=C81.08^^156^1952^43
 ;;^UTILITY(U,$J,358.3,40108,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40108,1,3,0)
 ;;=3^Nodular lymphocyte predom Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,40108,1,4,0)
 ;;=4^C81.08
 ;;^UTILITY(U,$J,358.3,40108,2)
 ;;=^5001399
 ;;^UTILITY(U,$J,358.3,40109,0)
 ;;=C81.48^^156^1952^28
 ;;^UTILITY(U,$J,358.3,40109,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40109,1,3,0)
 ;;=3^Lymp-rich classical Hodgkin lymphoma, lymph nodes mult site
 ;;^UTILITY(U,$J,358.3,40109,1,4,0)
 ;;=4^C81.48
 ;;^UTILITY(U,$J,358.3,40109,2)
 ;;=^5001439
 ;;^UTILITY(U,$J,358.3,40110,0)
 ;;=C81.18^^156^1952^44
 ;;^UTILITY(U,$J,358.3,40110,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40110,1,3,0)
 ;;=3^Nodular sclerosis class Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,40110,1,4,0)
 ;;=4^C81.18
 ;;^UTILITY(U,$J,358.3,40110,2)
 ;;=^5001409
 ;;^UTILITY(U,$J,358.3,40111,0)
 ;;=C81.28^^156^1952^36
 ;;^UTILITY(U,$J,358.3,40111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40111,1,3,0)
 ;;=3^Mixed cellular classical Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,40111,1,4,0)
 ;;=4^C81.28
 ;;^UTILITY(U,$J,358.3,40111,2)
 ;;=^5001419
 ;;^UTILITY(U,$J,358.3,40112,0)
 ;;=C81.38^^156^1952^30
 ;;^UTILITY(U,$J,358.3,40112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40112,1,3,0)
 ;;=3^Lymphocy depleted class Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,40112,1,4,0)
 ;;=4^C81.38
 ;;^UTILITY(U,$J,358.3,40112,2)
 ;;=^5001429
 ;;^UTILITY(U,$J,358.3,40113,0)
 ;;=C82.98^^156^1952^26
 ;;^UTILITY(U,$J,358.3,40113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40113,1,3,0)
 ;;=3^Follicular lymphoma, unsp, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,40113,1,4,0)
 ;;=4^C82.98
 ;;^UTILITY(U,$J,358.3,40113,2)
 ;;=^5001549
 ;;^UTILITY(U,$J,358.3,40114,0)
 ;;=C84.08^^156^1952^42
 ;;^UTILITY(U,$J,358.3,40114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40114,1,3,0)
 ;;=3^Mycosis fungoides, lymph nodes of multiple sites
